In this episode, we discuss the rising prevalence of pancreatic cancer and the promising treatment being developed by Oncolytics Biotech Inc. called pelareorep. The GOBLET study is currently testing pelareorep in combination with mFOLFIRINOX and atezolizumab in newly diagnosed metastatic pancreatic cancer patients, with positive results in previous trials and Fast Track Designation from the FDA. This innovative therapy could offer new hope for pancreatic cancer patients and improve outcomes.
